Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have at least one tumour that can be measured using standard imaging guidelines
• For Part A: People who have been confirmed (by lab testing of tissue or cells) to have an advanced or spreading solid tumour that cannot be surgically removed, and who have already tried other treatments, or for whom other treatments are not available or not tolerated
• For Part B: People confirmed to have a type of lung cancer (NSCLC) without certain specific genetic changes (such as EGFR or ALK mutations), with scan evidence that their cancer has grown despite prior treatment; or people confirmed to have advanced or spreading pancreatic cancer (PDAC) whose cancer has progressed after prior treatment, or for whom other treatments are not available or not tolerated
• For Part C: People confirmed to have NSCLC without certain specific genetic changes (such as EGFR or ALK mutations), with scan evidence that their cancer has grown despite prior treatment
• For Part D, Cohort D1: People confirmed to have pancreatic ductal adenocarcinoma (PDAC) who have not yet received treatment for advanced or spreading disease, and whose cancer may be suitable for a standard chemotherapy combination (gemcitabine plus nab-paclitaxel)
• For Part D, Cohort D2: People confirmed to have NSCLC without certain specific genetic changes, with scan evidence that their cancer has grown despite prior treatment including at least one standard chemotherapy course
• For Part D, Cohort D3: People confirmed to have NSCLC without certain specific genetic changes, who have not yet received treatment and have no medical reasons preventing them from receiving a standard chemotherapy combination (carboplatin plus pemetrexed)
• For Part D, Cohort D4: People confirmed to have NSCLC without certain specific genetic changes, who have not yet received treatment and whose cancer may be suitable for a standard first-line combination of pembrolizumab, carboplatin, and pemetrexed
• People who are able to provide a tumour tissue sample (either from a previous biopsy or a new one), unless the trial doctor determines this would pose a risk
• People with a general health and activity level rated as fully active or with only minor restrictions (ECOG score of 0 or 1)
• People whose heart, liver, kidneys, and other organs are functioning adequately at the time of screening

Who may not be able to join:

• People who are pregnant or currently breastfeeding
• Women who are able to become pregnant and are not using adequate contraception
• People who have an autoimmune disease that required systemic treatment in the past 12 months, or who have a history of autoimmune disease that may return
• People who have needed regular corticosteroids or other immune-suppressing medications within the 14 days before starting the trial treatment
• People who have previously experienced a severe (Grade 3 or higher) immune-related side effect, such as serious lung inflammation, heart muscle inflammation, or similar conditions
• People who have untreated cancer spread to the brain or central nervous system, or where such spread has continued to worsen
• People who have significant heart problems or reduced heart function
• People who have severe nerve damage (Grade 3 or higher neuropathy)
• People who have had extensive radiation therapy within the past 4 weeks, or limited targeted radiation within the past 2 weeks, or who have not yet recovered from side effects of prior cancer treatment
• People who are currently taking warfarin (Coumadin®) or similar blood-thinning medications at treatment doses, with the last dose within 5 days of starting the trial

Important: Always verify eligibility with the trial site directly before applying.